DUBLIN, Sept. 3, 2019 /CNW/ -- Endo International
plc (NASDAQ: ENDP) announced today that one of its operating
companies, Par Pharmaceutical (Par), has begun shipping an
authorized generic version of Merck's Noxafil®
(posaconazole) delayed-release tablets, 100 mg. Endo's subsidiary,
Endo Ventures Limited, recently entered into an exclusive U.S.
supply and distribution agreement with a subsidiary of Merck &
Co., Inc., of Kenilworth, N.J.
allowing Par to launch and distribute an authorized generic version
of the product. The agreement also includes rights to
posaconazole 40mg/mL oral suspension which Par intends to launch in
the coming months.
"Par is pleased to provide patients and providers with
access to a lower-cost treatment through our launch of the
authorized generic version of Noxafil®," said
Domenic Ciarico, Executive Vice
President & Chief Commercial Officer, Sterile & Generics at
Endo. "We are proud to add this differentiated product to our
portfolio."
Noxafil® is a registered trademark of Merck Sharp
& Dohme Corp.
About Endo International plc
Endo International
plc (NASDAQ: ENDP) is a highly focused generics and specialty
branded pharmaceutical company delivering quality medicines to
patients in need through excellence in development, manufacturing
and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in
Malvern, PA. Learn more at
www.endo.com.
About Par Pharmaceutical
Par Pharmaceutical,
headquartered in Chestnut Ridge,
NY, develops, manufactures and markets safe, innovative and
cost-effective generic pharmaceutical and branded injectable
products that help improve patient quality of life. Par, among the
top leaders in the U.S. generics industry, possesses a portfolio
that includes sterile injectables, alternative dosage forms and
many other differentiated products. Par is advancing a
robust research and development (R&D) pipeline of potential
products. Par is an operating company of Endo International
plc. Learn more at www.endo.com or www.parpharm.com.
Cautionary Note Regarding Forward-Looking
Statements
Certain information in this press release
contains certain "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 and applicable
Canadian securities legislation, including, but not limited to,
statements relating to the intent to launch products in the future
and product availability. Statements including words such as
"believes," "expects," "anticipates," "intends," "estimates,"
"plan," "will," "may," "look forward," "intend," "guidance,"
"future" or similar expressions are forward-looking statements.
Because these statements reflect Endo's current views, expectations
and beliefs concerning future events, these forward-looking
statements involve risks and uncertainties. Investors should note
that many factors, as more fully described under the caption "Risk
Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings with
the Securities and Exchange Commission and in
Canada on the System for
Electronic Data Analysis and Retrieval and as otherwise enumerated
herein or therein, could individually or in the aggregate affect
Endo's future financial results and could cause Endo's actual
results to differ materially from those expressed in the
forward-looking statements or from historical results. The
forward-looking statements in this press release are qualified by
these risk factors. Endo assumes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future developments or otherwise, except as may be
required under applicable securities laws.
View original
content:http://www.prnewswire.com/news-releases/endo-launches-authorized-generic-version-of-noxafil-posaconazole-delayed-release-tablets-in-the-united-states-300910365.html
SOURCE Endo International plc